Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168787 · ClinicalTrials.gov registry record
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 6,558
- Enrollment target
NCT05168787 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 6,558 participants.
The verdict
NCT05168787 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 6,558 participants
- Enrollment target
Study Summary
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general. However, the mechanism of action of sacubitril specifically targets the activity of BNP. Therefore, there is the potential that the mechanism of action of sacubitril/valsartan may be less effective in AAs.
Interventions
- DRUG sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,558 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2025-07-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05168787
The ClinicalTrials.gov registry entry for NCT05168787 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sacubitril/valsartan is the first listed.
NCT05168787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05168787 about?
NCT05168787 is a clinical study titled "Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction". There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general. However, the mechanism of action of sacubitril specifically targets the activity of BNP. Therefore, the...
What is the current status of trial NCT05168787?
This trial is currently completed. The enrollment target is 6,558 participants. The study started on 2020-08-13. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT05168787?
The interventions under investigation include: sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT05168787?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.